Screener
Kymera Therapeutics KYMR Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Total assets | $1,645,444 | $1,742,812 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $8,918 | $4,015 |
| Accrued expenses (Note 8) | 48,476 | 42,274 |
| Deferred revenue | — | 22,925 |
| Operating lease liabilities | 12,119 | 11,941 |
| Finance lease liabilities | 1,577 | 1,815 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's accounts payable?
- Kymera Therapeutics (KYMR) reported accounts payable of $8.92M in Q2 2026.
- How has Kymera Therapeutics's accounts payable changed year-over-year?
- Kymera Therapeutics's accounts payable increased by 54.3% year-over-year, from $5.78M to $8.92M.
- What is the long-term trend for Kymera Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Kymera Therapeutics's accounts payable has grown at a -1.7% compound annual growth rate (CAGR), from $4.37M to $4.02M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Kymera Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude